Novo Nordisk (NYSE: NVO) has added billions of dollars in market capitalization over the ongoing craze around the GLP-1 anti-obesity and anti-diabetes drugs. However, the Danish pharma giant’s most recognizable weight loss drug, Wegovy, is increasingly looking like a stepping stone instead of the promised panacea for the obesity pandemic. For the benefit of those who might not be aware, the GLP-1 hormone plays an important role in suppressing hunger and regulating the production of insulin and glucose. After a meal, GLP-1 agonists raise the level of insulin, which decreases blood glucose levels. Simultaneously, these drugs reduce the speed at […]
Read full article at https://wccftech.com/novo-nordisk-glp-1-weight-loss-drug-wegovy-is-not-a-panacea-for-obesity/
